Trials / Completed

CompletedNCT00465075

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

An Open-Label, Single-Dose, 3-Period, Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of Bazedoxifene Acetate/Conjugated Estrogens (Premarin© New Process) Administered Orally To Healthy, Postmenopausal Women

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 24 (estimated)

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex: Female
Age: 35 Years – 70 Years
Healthy volunteers: Accepted

Summary

The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.

Conditions

Healthy

Interventions

Type	Name	Description
DRUG	Bazedoxifene/conjugated estrogens combination

Timeline

Start date: 2007-03-01
Completion: 2007-04-01
First posted: 2007-04-24
Last updated: 2007-12-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00465075. Inclusion in this directory is not an endorsement.